JT-15

JT-15 is a small molecule curcumin analog being developed by Canget BioTekpharma for the treatment of various solid tumors, including ovarian, lung, and colon cancers. As a synthetic derivative of curcumin, JT-15 is designed to improve upon the pharmacological limitations of natural curcumin, such as poor aqueous solubility and low systemic bioavailability, while retaining or enhancing its anti-tumor properties. The drug is currently in the preclinical stage of development, with in vitro studies demonstrating activity against multiple cancer cell lines. While its specific molecular targets have not been explicitly disclosed, curcumin analogs typically modulate pleiotropic signaling pathways involved in cell proliferation, apoptosis, and inflammation.